Related references
Note: Only part of the references are listed.Wnt signaling pathway in cancer immunotherapy
Yang Zhou et al.
CANCER LETTERS (2022)
Deubiquitylase OTUD6B stabilizes the mutated pVHL and suppresses cell migration in clear cell renal cell carcinoma
Kai Guo et al.
CELL DEATH & DISEASE (2022)
Complementary roles of surgery and systemic treatment in clear cell renal cell carcinoma
Alexandre Ingels et al.
NATURE REVIEWS UROLOGY (2022)
FBXO2 targets glycosylated SUN2 for ubiquitination and degradation to promote ovarian cancer development
Jing Ji et al.
CELL DEATH & DISEASE (2022)
Arterial Stiffness and the Canonical WNT/β-catenin Pathway
Alexandre Vallee
CURRENT HYPERTENSION REPORTS (2022)
New Therapeutic Interventions for Kidney Carcinoma: Looking to the Future
Lucio Dell'Atti et al.
CANCERS (2022)
Circular RNA circ-TNPO3 inhibits clear cell renal cell carcinoma metastasis by binding to IGF2BP2 and destabilizing SERPINH1 mRNA
Xiaojuan Pan et al.
CLINICAL AND TRANSLATIONAL MEDICINE (2022)
USP13 promotes deubiquitination of ZHX2 and tumorigenesis in kidney cancer
Haibiao Xie et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2022)
Roles of the Dynamic Tumor Immune Microenvironment in the Individualized Treatment of Advanced Clear Cell Renal Cell Carcinoma
Enyu Lin et al.
FRONTIERS IN IMMUNOLOGY (2021)
Sec62 promotes stemness and chemoresistance of human colorectal cancer through activating Wnt/β-catenin pathway
Xiaofeng Liu et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2021)
Immunological perspective on the malignant progression of renal clear cell carcinoma
Ji Liu et al.
ANNALS OF TRANSLATIONAL MEDICINE (2021)
The Wnt signaling pathway in tumorigenesis, pharmacological targets, and drug development for cancer therapy
Zhuo Wang et al.
BIOMARKER RESEARCH (2021)
Hypoxia-Inducible Factor-2α as a Novel Target in Renal Cell Carcinoma
Won Seok W. Choi et al.
JOURNAL OF KIDNEY CANCER AND VHL (2021)
ATF-2 and Tpl2 regulation of endothelial cell cycle progression and apoptosis
Gareth W. Fearnley et al.
CELLULAR SIGNALLING (2020)
B7-H3 promotes colorectal cancer angiogenesis through activating the NF-κB pathway to induce VEGFA expression
Ruoqin Wang et al.
CELL DEATH & DISEASE (2020)
Structural basis of semaphorin-plexin cis interaction
Daniel Rozbesky et al.
EMBO JOURNAL (2020)
VHL mutation-mediated SALL4 overexpression promotes tumorigenesis and vascularization of clear cell renal cell carcinoma via Akt/GSK-3β signaling
Jinbo Sun et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2020)
Semaphorin 6A Attenuates the Migration Capability of Lung Cancer Cells via the NRF2/HMOX1 Axis
Li-Han Chen et al.
SCIENTIFIC REPORTS (2019)
Current Concepts of Non-Coding RNAs in the Pathogenesis of Non-Clear Cell Renal Cell Carcinoma
Dominik A. Barth et al.
CANCERS (2019)
Hypoxia-inducible factor (HIF)-prolyl hydroxylase 3 (PHD3) maintains high HIF2A mRNA levels in clear cell renal cell carcinoma
Petra Miikkulainen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2019)
VHL-Mediated Regulation of CHCHD4 and Mitochondrial Function
Thomas Briston et al.
FRONTIERS IN ONCOLOGY (2018)
Homology modeling and molecular dynamics simulation of the HIF2α degradation-related HIF2α-VHL complex
Xiaotian Dong et al.
JOURNAL OF MOLECULAR GRAPHICS & MODELLING (2017)
Crystal Structure of the Cul2-Rbx1-EloBC-VHL Ubiquitin Ligase Complex
Teresa A. F. Cardote et al.
STRUCTURE (2017)
Development of Inhibitors Targeting Hypoxia-Inducible Factor 1 and 2 for Cancer Therapy
Tianchi Yu et al.
YONSEI MEDICAL JOURNAL (2017)
The regulation of β-catenin activity and function in cancer: therapeutic opportunities
Shuang Shang et al.
ONCOTARGET (2017)
Targeting HIF-2 α in clear cell renal cell carcinoma: A promising therapeutic strategy
Olga Martinez-Saez et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2017)
Review of renal cell carcinoma and its common subtypes in radiology
Gavin Low et al.
WORLD JOURNAL OF RADIOLOGY (2016)
Insulin and IGFs in renal cancer risk and progression
W. Solarek et al.
ENDOCRINE-RELATED CANCER (2015)
SEMA6A is a prognostic biomarker in glioblastoma
Jiaxin Zhao et al.
TUMOR BIOLOGY (2015)
Potential Approaches and Recent Advances in Biomarker Discovery in Clear-Cell Renal Cell Carcinoma
Weronika Majer et al.
JOURNAL OF CANCER (2015)
A 26-Gene Hypoxia Signature Predicts Benefit from Hypoxia-Modifying Therapy in Laryngeal Cancer but Not Bladder Cancer
Amanda Eustace et al.
CLINICAL CANCER RESEARCH (2013)
Relation of a hypoxia metagene derived from head and neck cancer to prognosis of multiple cancers
Stuart C. Winter et al.
CANCER RESEARCH (2007)